Patch Biosciences utilizes an AI-driven platform for sequence design to engineer gene therapies, enhancing the specificity and durability of genetic medicines. The company addresses the need for more effective therapeutic solutions in the biopharmaceutical industry by integrating advanced machine learning models with synthetic biology techniques.
Funding
Funding not disclosed
Founders
Product
Problem
Engineering effective gene therapies is challenging due to the need for precise sequence design to ensure specificity, durability, and efficacy of genetic medicines. Traditional methods often lack the sophistication to fully optimize these factors, hindering the development of more advanced therapeutic solutions.
Solution
Patch Biosciences (acquired by Ginkgo Bioworks) developed an AI-driven platform for sequence design to engineer gene therapies with enhanced specificity and durability. The platform integrates advanced machine learning models with synthetic biology techniques to optimize genetic medicine development. Patch's technology strengthens Ginkgo's Gene Therapy Services, Cell Therapy Services, and RNA Therapeutics Services by providing new capabilities in synthetic promoter and untranslated region (UTR) engineering. The platform also incorporates validated muscle promoters and robust RNA UTRs, complementing Ginkgo's circular RNA and promoter screening platform technology.
Target Audience
The primary customers are biopharmaceutical companies and researchers focused on developing advanced gene therapies, cell therapies, and RNA therapeutics.
Features
- AI-driven sequence design for enhanced specificity and durability of gene therapies
- Integration of machine learning models with synthetic biology techniques
- Synthetic promoter and untranslated region (UTR) engineering capabilities
- Validated muscle promoters and robust RNA UTRs